Sign In
Buy CLLS
$3.09
-0.290 (-8.58%)
At Close: Jun 03, 2026
Cellectis to Hold Fourth Quarter 2020 Earnings Call on Friday, March 5, 2021 at 8:00AM EST
04:30pm, Thursday, 25'th Feb 2021
NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited all
Cellectis, Cytovia Therapeutics Ink Gene-Edited Therapy Pact For Oncology Indications
08:55am, Tuesday, 16'th Feb 2021
Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have entered into a strategic research and development collaboration to develop TALEN gene-edited induced pluripotent stem cells (iPSC) N
Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells
01:00am, Tuesday, 16'th Feb 2021
CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and C
Cellectis: Monthly information on share capital and company voting rights
04:30pm, Wednesday, 10'th Feb 2021
(Article 223-16 of General Regulation of the French financial markets authority)
7 CRISPR Stocks for the Future of Medicine
06:12pm, Friday, 15'th Jan 2021
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on
Monthly information on share capital and company voting rights
04:30pm, Wednesday, 06'th Jan 2021
(Article 223-16 of General Regulation of the French financial markets authority)
Cellectis (CLLS) Jumps: Stock Rises 9%
12:47pm, Thursday, 17'th Dec 2020
Cellectis (CLLS) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
Cellectis Announces Withdrawal of Follow-On Offering
08:16pm, Tuesday, 15'th Dec 2020
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited all
Cellectis Announces Launch of Follow-On Offering
04:19pm, Monday, 14'th Dec 2020
NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS), a clinical-stage biopharmaceutical company focused on developing immun
Monthly information on share capital and company voting rights
04:30pm, Tuesday, 08'th Dec 2020
(Article 223-16 of General Regulation of the French financial markets authority)
NEW YORK, Dec. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited all
Regenerative Medicines: Universal Cell Therapy Gaining Momentum
08:03am, Tuesday, 01'st Dec 2020
Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 mo
FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis' Product Candidate UCARTCS1 in Multiple Myeloma
08:00pm, Tuesday, 17'th Nov 2020
NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-c
Cellectis Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer
04:30pm, Monday, 16'th Nov 2020
NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited all
Monthly information on share capital and company voting rights
04:30pm, Friday, 06'th Nov 2020
(Article 223-16 of General Regulation of the French financial markets authority)
